Gregor Heinecke

Gregor Heinecke is founder and Managing Director of DermoTech GmbH, a startup medical device company active in research and development of UV free blue light phototherapy technology. The innovation is a breakthrough therapy for atopic dermatitis, a widespread disease, and other autoimmune diseases for being causal and inexpensive. The therapy has been confirmed in pilot studies and will add a valuable treatment option because it is most eligible for children and free of side effects. Gregor has been awarded as winner of the Life Sciences Venture Market at the Charité BIH Entrepreneurship Summit 2021. Prior to his committment to medical innovation, he gained over 10 years of experience in investment banking and corporate finance, with focus on Mergers & Acquisitions for large international and SME customers. Gregor studied at the Goethe University Frankfurt, Germany, and a the University of St. Gallen, Switzerland, graduating with a degree in Business Administration (lic. oec. HSG).